Pimecrolimus 1% cream for the treatment of rosacea.

Abstract

Rosacea is a common inflammatory skin disorder; the pathogenesis is unclear. Various treatment options for rosacea are available, but most have limited effectiveness. The aim of this study was to investigate the efficacy and safety of 1% pimecrolimus cream for the treatment of rosacea. Thirty patients with rosacea were enrolled in this 4-week, single-center, open-label study of 1% pimecrolimus cream. Patients were instructed to apply the cream to their faces twice daily and were not permitted to use any other agents. Clinical efficacy was evaluated by a rosacea grading system using photographic documentation and a mexameter. The 26 patients who completed the study experienced significantly reduced rosacea clinical scores from 9.65 ± 1.79 at baseline to 7.27 ± 2.11 at the end of treatment (P < 0.05). The mexameter-measured erythema index decreased significantly from 418.54 ± 89.56 at baseline to 382.23 ± 80.04 at week 4 (P < 0.05). The side-effects were mostly transient local irritations. The results of this study suggest that 1% pimecrolimus cream is an effective and well-tolerated treatment for patients with mild to moderate inflammatory rosacea.

• Authors: Moon-Bum Kim, Gun-Wook Kim, Hyun-Je Park, Hoon-Soo Kim, Hyun-Woo Chin, Su-Han Kim, Byung-Soo Kim, Hyun-Chang Ko
• Journal: The Journal of dermatology (J Dermatol) Vol. 38 Issue 12 Pg. 1135-9 (Dec 2011) ISSN: 1346-8138 [Electronic] England
• PMID: 21954922 (Publication Type: Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
• Copyright: © 2011 Japanese Dermatological Association.

Chemical References

• Calcineurin Inhibitors
• Dermatologic Agents
• pimecrolimus
• Tacrolimus

Topics

• Administration, Topical
• Calcineurin Inhibitors
• Dermatologic Agents (administration & dosage)
• Female
• Humans
• Male
• Middle Aged
• Rosacea (drug therapy, pathology)
• Tacrolimus (administration & dosage, analogs & derivatives)
• Treatment Outcome